Unlocking the Value of Data at CDMOs

What Does It Take to Be a Modern CDMO?

In order to keep up with the increasing reliance from the industry and to stand out from the growing competition, the modern CDMO must leverage their must important asset: data.

Leveraging data at a CDMO will provide for:

Quality and Regulatory Assurance, through enhanced process understanding and control
Increased Partner Trust, through increased external collaboration and process transparency
Maximized Revenue, through COGs optimization and accelerated delivery times

How can CDMOs unlock the value of data?

Data is the new oil. However, just like oil, data needs to be refined and properly put to work. Sartorius Data Analytics is the leading provider of advanced data analytics solutions to the biopharmaceutical industry. Our data refinement offerings include MODDE^®, for design of experiments, SIMCA^®for multivariate data analysis, and SIMCA^®-online for real-time process monitoring.

Putting the “D” in CDMO with Data Analytics and Ambr®

Biopharmaceutical companies have placed an increased reliance on contract development and manufacturing organizations (CDMOs) for all aspects of process development. However, as a CDMO, how can ensure that you’ll be able to meet the aggressive timeline expectations set out by your clients? In this webinar, Sartorius experts will discuss how to combine Ambr® multi-parallel systems with tools from the Umetrics® Suite in order to accelerate process development timelines. Our experts will answer questions like: “Why and how do you perform DOE and QbD studies with Ambr®?” and “how can the power of MVDA be utilized to decipher my Ambr® data?”. Sign-up for this webinar to learn more about how your organization can use data driven decisions to meet deadlines and secure partner-client trust.

How CDMOs Can Use Data Analytics as a New Source of Revenue

The global biologics market is one of the fastest growing segments of the pharmaceutical industry. Annual revenues are expected to exceed $300 billion in the next 2-3 years.¹ But development and production can’t keep pace with discovery. That’s one reason outsourcing to contract development and manufacturing organizations (CDMOs) continues to increase. CDMOs, which currently represent 20% of the industry’s manufacturing capacity, are expected to grow to 30% of global manufacturing volume by 2025.

How CDMOs Can Implement a Modular PAT Strategy

Process analytical technology (PAT) is playing an increasingly important role in the pharmaceutical and biopharmaceutical industries due to regulatory pressure and the push to reduce costs while managing quality. For CDMOs, any investments into PAT technology must be versatile enough to accommodate a variety of products and processes.

That’s why a modular approach to PAT – including robust data analytics tools – can help CDMOs meet regulatory requirements while managing product quality and reducing costs.

How Data Analytics can Boost the Bottom Line at a CDMO

With new technologies come new business opportunities. In this webinar Sartorius will present how to data analytics can be used to maximize productivity and profitability at a contract (bio)pharma organization. On top of the more commonly known benefits, like reducing batch variability, data analytics also provides a unique upsell opportunity for CDMOs.

By innovating their service offerings, CDMOs can address some of the major challenges their partners face when deciding to outsource their operations, like loss of control or quality management. In this webinar, we will propose a scenario in which a CDMO can double its’ return of investment in just one year! At the end of the day, CDMO’s who choose to innovate their offerings can secure higher value contracts, grow their sales pipelines, and attract long-term strategic partners.

OSIsoft and Sartorius Partner to Help CDMOs Leverage their Data

Achieving profitability, growth and staying ahead of competitors means leveraging one of your most important assets: data. As the CDMO market consolidates and becomes more competitive, those who tap into the real value of data can use it to gain recognition as strategic differentiators, provide market leadership, and ultimately become more profitable.

In this presentation, Sartorius Data Analytics will present on how contract pharma organizations can gain additional insights from their data while increasing partner trust and collaboration using SIMCA®, SIMCA®-Q and SIMCA®-online connected to the OSIsoft PI System. The presentation will showcase a success story from FUJIFILM Diosynth Biotechnologies. At this CDMO, pairing the OSIsoft PI System with advanced data analytics tools from Sartorius enabled a tenfold optimization in resource expenditure, reduced paper footprint by ~10,000 sheets/year, and increased partner trust and collaboration opportunities.